3.6 Medication-Assisted Treatment (MAT/MOUD)

Why MAT Is on the Exam (and the Newer Term MOUD)

The federal government and SAMHSA increasingly use Medications for Opioid Use Disorder (MOUD) in place of "medication-assisted treatment" to emphasize that pharmacotherapy is treatment, not a crutch or a lesser path. The IC&RC blueprint expects counselors to know each medication's mechanism, regulatory setting, common side effects, contraindications, and the counselor's role. Counselors do not prescribe, but they must understand the medications well enough to support adherence and counter stigma.

Medications for Opioid Use Disorder

1. Methadone

• Mechanism: full mu-opioid receptor agonist; long half-life (24-36 hours) allows once-daily dosing without intoxication when titrated.
• Setting: FDA-approved for OUD only when dispensed through a federally certified Opioid Treatment Program (OTP). (Methadone may be prescribed for pain in any setting, but not for OUD outside an OTP.)
• Common side effects: sedation, constipation, sweating, QT-interval prolongation at higher doses, hypogonadism with long-term use.
• Evidence: strongest data for treatment retention and reductions in illicit opioid use, mortality, and HIV/HCV transmission. The most tightly regulated of the three.

2. Buprenorphine

• Mechanism: partial mu-opioid agonist with high receptor affinity and a ceiling effect on respiratory depression, giving it a wider safety margin than methadone. Often combined with naloxone (as Suboxone) to deter diversion via injection.
• Setting: office-based. The DATA-2000 X-waiver was eliminated by Section 1262 of the Consolidated Appropriations Act of 2023 (the MAT Act). Any clinician holding a current DEA registration with Schedule III authority may now prescribe buprenorphine for OUD; the former patient cap was also removed.
• Common side effects: headache, constipation, sweating, insomnia, nausea.
• Critical induction issue: precipitated withdrawal if started before the client is already in mild-to-moderate opioid withdrawal (typically a COWS — Clinical Opiate Withdrawal Scale — score of about 8-12). Counselors should recognize the term and the timing risk.

3. Naltrexone (Extended-Release: Vivitrol)

• Mechanism: mu-opioid receptor antagonist — it blocks opioids, produces no opioid effect, causes no dependence, and has no diversion value.
• Formulation: oral (50 mg daily) or extended-release intramuscular injection, 380 mg every 4 weeks.
• Setting: any qualified prescriber; no DEA-specific waiver required.
• Critical requirement: the client must be opioid-free for 7-10 days (longer for long-acting opioids such as methadone or buprenorphine) before the first dose, or naltrexone will trigger precipitated withdrawal severe enough to require hospitalization.
• Common side effects: injection-site reactions, nausea, headache, fatigue; rare hepatotoxicity at very high doses. A key safety point: tolerance drops after stopping, so overdose risk rises if the client returns to opioids.

Medications for Alcohol Use Disorder

Off-label options include topiramate and gabapentin, increasingly supported in the AUD literature but not FDA-approved for AUD.

Other MAT

• Tobacco use disorder: nicotine replacement therapy, varenicline (Chantix), and bupropion.
• Stimulant and cannabis use disorders: no FDA-approved medications exist; treatment is psychosocial (CBT, contingency management).

The Counselor's Role with MAT

Counselors do not prescribe, but they do:

• Educate the client and family on how the medication works.
• Support adherence — confront ambivalence, problem-solve logistical barriers (daily OTP dosing, the monthly injection schedule).
• Monitor for side effects and refer promptly back to the prescriber.
• Integrate counseling — the MOUD evidence base assumes paired psychosocial treatment.
• Address stigma — within families, in 12-step meetings, and in the counselor's own attitudes. SAMHSA states plainly that clients on methadone or buprenorphine are in recovery, not "still using."
• Coordinate care with the prescriber, OTP, pharmacy, and probation when relevant.

Stigma and Common Myths the Exam Targets

• Myth: "MAT is just trading one drug for another." The exam expects you to identify this as stigma; the medications restore receptor function and prevent overdose.
• Myth: "Clients on MAT cannot work the steps." Most major mutual-aid organizations now accept members on MOUD, though individual meetings vary.
• Myth: "Tapering off MOUD quickly is success." Premature taper is one of the strongest predictors of relapse and overdose death; duration is individualized and often long-term.

Agonist vs Partial Agonist vs Antagonist: The One Concept That Unlocks the Section

If you understand the three receptor actions, you can reason through most MOUD items without memorizing every detail:

• A full agonist (methadone) fully activates the mu-opioid receptor — effective and retention-strong, but with overdose risk if dosed too high or combined with other sedatives, hence the OTP controls.
• A partial agonist (buprenorphine) only partially activates the receptor and has a ceiling effect, so beyond a certain dose respiratory depression does not increase — a built-in safety margin. Its high affinity also displaces other opioids, which is exactly why it can precipitate withdrawal if started too early.
• An antagonist (naltrexone) occupies the receptor without activating it, blocking any opioid effect — no euphoria, no dependence, no diversion value, but it offers no relief from withdrawal and demands a clean opioid-free window first.

Naloxone: Overdose Rescue, Not Maintenance

Do not confuse naloxone (Narcan) with naltrexone. Naloxone is a short-acting opioid antagonist used for acute overdose reversal — administered intranasally or by injection by bystanders and first responders, it can be repeated because its duration is shorter than many opioids. It is not a maintenance medication. Counselors should know overdose-recognition signs (pinpoint pupils, respiratory depression, unresponsiveness) and ensure clients and families have naloxone and training, especially after any period of reduced tolerance (post-detox, post-incarceration, after stopping naltrexone).

Harm Reduction and the Counselor

MOUD sits within a broader harm-reduction philosophy that the exam treats as evidence-based and non-judgmental: meeting clients where they are, keeping them alive and engaged, and reducing the consequences of use even before abstinence. Counselors support harm-reduction measures — naloxone access, fentanyl test strips, safer-use education, syringe services, and not discharging a client merely for a positive screen — alongside, not in opposition to, recovery goals.

Pregnancy and Special Populations

A high-stakes point: for pregnant clients with OUD, methadone or buprenorphine is the standard of care; medically supervised withdrawal is generally discouraged because it carries higher relapse and fetal risk. Counselors do not advise a pregnant client to stop MOUD; they coordinate with the prescriber and obstetric team.